Method of increasing biological properties of antiseptic-stimulator of dorogov asd-2f
SUBSTANCE: increase in biocidal and immunobiological action due to the use of distilled water ionised with silver ions and adding into the composition of succinic, ascorbic, citric acid and aethonium.
EFFECT: increase in biocidal immunobiological properties of the antiseptic-stimulant of Dorogov ASD-2F.
6 ex, 1 tbl
The invention relates to biotechnology.
Known methods of increasing the effectiveness of ASD-2F with succinic and ascorbic acids, vitamins A and E (Isidima), metallocenter, formaldehyde, levamisole (Reference "Vidal vet", 2013, 32-33, patent RF №2303979 "Amber biostimulant, publ. 10.08.2007 G., patent RF №2351323 "Method of producing integrated product", publ. 10.04.2008; A. A. Iglewski, V. N. Skhirat "Modified levamisol - effective anthelmintic drug, veterinary science, No. 8, 2010, pp. 48-51; A. A. iglewski, T. I. Mikhaleva, O. N. Mikhailov "Immunometabolic drug activity on the basis of succinic acid and levamisole". Journal of the Kursk state agricultural Academy, No. 1, 2013, p. 64; A. A. Iglesia, G. F. Ryzhov, O. M. Shvets, "Development of a new generation immunometabolic drugs and the effectiveness of their use in veterinary medicine with the use of formaldehyde and trace elements." Journal of the Kursk state agricultural Academy, No. 5, 2010, pp. 70-71).
The disadvantage of these modifications with formaldehyde, levamisole is what is known by the decision who formaldehyde as carcinogenic drug with insufficient detoxifying effect - not recommended in the manufacture of vaccines, toxoids (Biologicals, M., 2001, No. 1, pp. 22-23).
The above disadvantages have caused the need to increase the biocidal and immunobiological properties of the ASD-2F and its modifications.
taken as a prototype method for producing a modified ASD-2F titled "Acidific", which contains the ASD-2F, succinic acid and vitamins A and E (Reference "Vidal vet", 2013, 32-33).
The disadvantage of this method are the insolubility of vitamins A and E in aqueous solutions and no biocidal effect on viruses and fungi.
An object of the invention is to increase the biocidal immunobiological properties of an antiseptic-stimulator Dorogova ASD-2F.
The technical result is to increase the biocidal and immunobiological action through the use of ionized silver ions with distilled water and making the composition of succinic, ascorbic, citric acids and etoniya.
The technical result is achieved by introducing 100 ml of a solution of ASD-2F 200 mg amber, 100 mg ascorbic, 100 mg of citric acid and etoniya 100 mg with subsequent activation of 1 mg of colloidal silver ions.
The results are presented the following examples.
Example 1.The study of shelf life.
The solutions of the modified antiseptic-stimulator Dorogova ASD-2F retain their original properties and appearance within 2 years (observation period).
Example 2.The definition of harmlessness of the drug.
Daily subcutaneous and intramuscular injection for 5 days 40 calves for 5.0 ml and 60 piglets 3.0 ml did not cause animals to increase the temperature of � necrotic lesions areas of the body at the injection site.
Example 3. The study of the biocidal properties of the drug.
The study of the biocidal properties were carried out in respect of the suspension 10 thousand/ml Staphylococcus, Salmonella, E. coli, fungi by mixing the modified ASD 2F in the ratio 1:1, 1:2 and 1:3, exposure of 60 minutes with subsequent seeding on nutrient medium.
The results are presented in the table.
From the data presented in the table, it follows that the bactericidal and fungicidal action ASD 2F and Acidific manifests itself in a dilution of 1:1 and the modified ASD-2F silver ions in a dilution of 1:1, 1:2 and 1:3, i.e. 2-3 times more concentrated than the original drugs.
Example 4. A method for the treatment of cows, patients with purulent-catarrhal mastitis.
The studies have used 68 cows sick with mastitis, which intracisternal were injected daily with 3-4 ml for 4-5 days with a syringe. In all animals of the treated residual processes mastitis is not installed.
Example 5. A method for the treatment of piglets, patients with dyspepsia.
Pigs (37 goals) - 1,5-2,0 months of age with pronounced diarrhea twice a day for 3-5 days gave feed 4-5 ml of the modified ASD-2F. All the 37 piglets after treatment returned to normal digestive processes. The diarrhea stopped, the side effects are not established.
Example 6. Treatment of dogs with lesions dermatitis the back and pelvic limbs.
In the experiment, 37 dogs 1-1,5 years of age of different breeds. To the affected areas of skin twice a day applied gauze soaked modified ASD-2F, and was subcutaneously injected once a day for 4-5 ml for 5-6 days. All the 37 dogs in 7-9 days stopped the lesions and scratching of the skin while normalizing skin and wool on the affected skin.
A method of improving the biocidal action against bacteria, viruses, pathogenic fungi antiseptic-stimulator Dorogova ASD-2F, characterized by introducing 100 ml of the drug solution 200 mg amber, 100 mg ascorbic, 100 mg of citric acid and etoniya 100 mg with subsequent activation of 1 mg of colloidal silver ions.
SUBSTANCE: method includes carrying out complex treatment at the background of diet therapy. Intake of antihelmintic of vegetable origin and immunomodulator is carried out daily with washing down each of them with 200 ml of radon water. Intestinal lavage is performed every second day. On days of performing intestinal lavage, patient takes bath with radon water in the morning before lavage, with performing underwater hydrodynamic massage (UHM) on other days. On days, when intestinal lavage is not performed, sessions of sound therapy are carried out after UHM.
EFFECT: method provides correction of biological age of organism as prevention of premature ageing.
3 cl, 4 tbl, 2 ex
SUBSTANCE: before Mantoux test with 2 TE PDD-L, Ergoferon preparation is used in the infants infected with tuberculosis mycobacteria with the suspected early period of primary tuberculosis infection and active tuberculosis infection, in a dose of 1 tablet 20-30 minutes before or after a meal, once a day for 45 days.
EFFECT: invention provides the complex preparation of frequently and chronically ill children with an allergic pathology, for Mantoux test with 2 TE PDD-L.
3 tbl, 2 ex
SUBSTANCE: before Mantoux test with 2 TE PPD-L, general advice for phthisiologist-controlled preparation of the infants are given. That is added with prescribing the immunomodulatory preparation Anaferon for children aged 1 year and older 1 tablet 20-30 minutes before and after meals once a day for 30 days.
EFFECT: invention provides the complex preparation of frequently and chronically ill children for Mantoux test with 2 TE PDD-L.
3 tbl, 2 ex
SUBSTANCE: invention relates to biotechnology, specifically to immunostimulating compounds and may be used in medicine. An immunostimulating peptide of an amino acid sequence XLYDKGYTSKEQKDCVGI, where N-terminal X is N-acetylalanine, and may be covalently linked to fatty acids, selected from C2-C25, to form PDAG (peptidyl-2,3-diacylglycerides). The resulted compound may be included in pharmaceutical formulations for stimulating an immune response.
EFFECT: invention provides efficient stimulation of an immune response in subjects and may enhance the immunogenicity of the antigenic peptide when administered with PDAG.
29 cl, 10 dwg, 9 ex
SUBSTANCE: first stage involves a cervical uterine repair by staged dissection on the 5-7th menstruation day in a combination with laser destruction of exophytic condylomas. Laser light power is 6-9 Wt, spot diameter is 1.5 mm, and exophytic condylomas penetration is 1-1.5mm. The second stage involves the immunomodulatory therapy.
EFFECT: method enables increasing the clinical effectiveness by recovering the immunological homeostasis of the uterine cervix by potentiating two effects: recovering archtechtonics of the cervical canal and immunomodulatory therapy.
4 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to new 2-amino-2-[2-(4-C2-20alkylphenyl)ethyl]propan-1,3-diol salts specified in tartrate, lactate benzoate, succinate, malonate, acetate and propionate in the crystalline form. Each of the above salts is characterised by powder X-ray pattern data. Compounds in the therapeutically effective amount can be used in treating autoimmune diseases.
EFFECT: crystalline salts of the present invention possess higher stability, better solubility, more convenient to store and handle.
11 cl, 7 dwg, 1 tbl, 10 ex
SUBSTANCE: invention mainly relates to a food composition, including punicalagins.
EFFECT: improved action in respect to health improvement.
8 cl, 1 tbl, 1 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention relates to field of organic chemistry, namely to heterocyclic compound of general formula (I) or to its pharmaceutically acceptable salt, acid salt or stereoisomer, where Y: NRa and N+R1R2X-; Z: bond, -(CH2)p, -CHOH, -CH=CH-, -C≡C-, -CONH- and -CO-; Rb: C1-C8 alkyl, C2-C8 alkenyl, C6-C10 aryl, -NR5R6,: , and ; with each alkyl, alkenyl and aryl, representing Rb, possibly, contains 1-3 substituents, selected from C1-C4 alkyl, C2-C4 alkenyl, C3-C6 cycloalkyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6- and 7-membered heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, halogen, -OH, -NH2, -CN and -NO2; Rc: halogen, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C1-C4 alkoxy, C6-C10 aryl, 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, 9- and 10-membered bicyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; with C1-C6 alkyl, C2-C6 alkenyl C2-C6 alkinyl, C3-C10 cycloalkyl, C3-C8 cycloalkenyl, C6-C10aryl, 5-, 6-, 7-, 8-membered monocyclic heterocyclyl and 9- and 10-membered bicyclic heterocyclyl, representing Rc, possibly contain 1-5 substituents, selected from the group, consisting of C1-C4 alkyl, C1-C4 alkoxy, C1-C4 haloalkyl, C1-C4 haloalkoxy, C3-C6 cycloalkyl, C4-C8 cycloalkenyla, halogen, -OH, -NH2, C6-C10 (A)(A')(A")(A'")aryl, (A)(A')(A")(A'")heterocyclyl, containing 1-3 heteroatom, selected from nitrogen, oxygen and sulphur, NR14R15, (CH2)pNR14R15, -CN, -NO2, oxo, -COOR14, SOR14, SO2R14, SO2NR14R15, NR15SO2R16, COR14, CONR14R15 and NR15COR16; with each (A), (A'), (A") and (A'")independently absent or representing C1-C4 alkyl, and each heterocyclyl (A)(A')(A")(A'")heterocyclyl is independently selected from the group, consisting of 5-, 6-, 7- and 8-membered monocyclic heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur, and 9- and 10-membered bicyclico heterocyclyl, containing 1-3 heteroatoms, selected from nitrogen, oxygen and sulphur; the remaining radicals have values given in i.1;and on condition that, if Rc represents heterocyclyl, said heterocyclyl is bound directly through carbon atom of heterocyclyl ring. Invention also relates to particular compounds and to pharmaceutical composition based on formula (I) compound.
EFFECT: obtained are novel imidazopyrazine and imidazodiazepine derivatives, useful for prevention or treatment of disease or condition, severity of which is reduced by receptors to cannabinoids.
21 cl, 5 dwg, 4 tbl, 71 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to isoxazoline FAAH inhibitors of formula (I) or their pharmaceutically acceptable forms, wherein each of G, Ra, Rb, Rc and Rd has a value described in the present application, to pharmaceutical compositions, and methods of treating a FAAH-mediated condition.
EFFECT: developing the method of treating the FAAH-mediated condition.
32 cl, 22 tbl, 351 ex
SUBSTANCE: immunocorrective agent for the therapy of atherosclerotic diseases containing hawthorn blossom, common St. John's wort herb, as well as calcium stearate and silicone oxide taken in certain proportions.
EFFECT: agent is effective for the therapy of atherosclerotic diseases.
SUBSTANCE: two-duct drain tube is intraoperatively inserted into a residual cavity. The tube is delivered onto an anterior abdominal wall. The cyst cavity is irrigated with 0.05% chlorhexidine every day from the second postoperative day that is followed by administering the preparation of 10% povidone iodine with the drain tube pinched for 3-5 minutes. The procedure is performed until the cyst cavity is eliminated completely.
EFFECT: method provides the reliable treatment of the residual cyst cavity following marsupialisation and open echinococcectomy, as well as prevents the postoperative complications by achieving the aseptic inflammation of the inner surface of the fibrous capsule surface followed by the cyst cavity obliteration.
2 dwg, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to a new hydrate of 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol hydrochloride salt in the crystalline form with the characteristics below. The hydrate can be used for producing a drug or for treating or preventing a transplanted organ or tissue rejection, or autoimmune diseases in a therapeutically effective amount. The above hydrate is characterised by an X-ray powder diffractogram having peaks at approximately 2.9, 17.2, 30.6, 28.2, 24.4, 8.6 and 25.9 degrees 2-Theta with a limit of error of ±0.2 degrees for each value of 2θ, having a purity of 90% or more, and containing 5.2 to 5.9% of water.
EFFECT: invention also characterises a pharmaceutical composition with using the above hydrate.
4 cl, 4 dwg, 8 tbl, 14 ex
SUBSTANCE: invention can be used for the local treatment of trophic ulcers, infected and persistent septic wounds, degrees I-II-IIIA burns, traumatic skin injuries, pyoinflammatory skin diseases, bed sores, etc. The invention refers to a preparation, which contains a streptocide powder 1-2.5 g, Ichthyol ointment 7-10 g and castol oil 87.5-92 ml.
EFFECT: reducing the length of treatment up to 14 days with no side effects.
SUBSTANCE: invention relates to medicine, namely to veterinary and veterinary obstetrics, and can be applied for the treatment of clinical mastitis in cows. For this purpose after evening milking for 4 days, parts of the udder with signs of mastitis are influenced with an alternating magnetic field from the magnetic-therapeutic apparatus AMnp-02 "Solnyshko". The duration of exposure constitutes 10 minutes. Mastoxidine, heated to 40°C, in a dose of 20 ml three days successively, is additionally intracisternally introduced for 3 days running.
EFFECT: method ensures an increase of the treatment efficiency due to the enforcement of mastoxidine action at deep cellular and intra-cellular levels with the acceleration of its penetration in tissues.
1 dwg, 2 tbl, 2 ex
SUBSTANCE: therapeutic agent contains hypromellose, boric acid and a consistency base; it additionally contains anesthesin or lidocaine as an analgesic in an amount of 0.00001-0.5 g.
EFFECT: fixing a lubricating agent on the catheter enabling preventing mucosal injuries accompanying a drainage procedure, and eliminating side effects.
3 cl, 6 ex
FIELD: veterinary medicine.
SUBSTANCE: preparation for treatment of infected wounds in the toe region of animals, containing dimethyl sulphoxide, methyl cellulose, additionally comprises tylosin tartrate, sulphadimine, trimethoprim in the following ratio of components, wt %: tylosin tartrate - 2-3, sulphadimine - 4-5, trimethoprim - 1-1.5, dimethyl sulphoxide - 10-15, methylcellulose - 3.0-3.5, water - the rest. The claimed method comprises applying the claimed preparation without preliminary wound cleaning. The preparation is applied to the wound with the layer thickness of 2-3 mm, without application of soft dressing. The treated animals are kept for 2-3 hours on the dry surface.
EFFECT: use of claimed group of inventions increases the efficiency of treatment.
4 cl, 7 tbl, 2 ex
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition for treating gastroduodenal ulcer in the form of tablets, capsules or gel, containing therapeutic agents and a consistency base applicable for each dosage, wherein the therapeutic agents are as follows: recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; antiseptics; amino acids specified in a group: arginine, histidine, lysine, cysteine, methionine, glutamic acid; and antioxidants specified in a group: beta-carotene, vitamin C, vitamin E.
EFFECT: invention has the integrated body effect promoting faster healing of the mucosal defect accompanying the aggravated gastroduodenal ulcer and preventing recurrences, including by the eradication effect.
6 cl, 5 ex
FIELD: veterinary medicine.
SUBSTANCE: pharmaceutical composition in the form of ointments for treatment of mastitis in cows comprises n-tetradecyltributylphosphonium bromide as active ingredient and petrolatum as an excipient at the ratio of 1:2000.
EFFECT: invention provides a pharmaceutical composition in the form of an ointment, which is new in mechanism of action, effective when applied topically at low therapeutic concentration.
FIELD: medicine, pharmaceutics.
SUBSTANCE: invention refers to medicine, and concerns a pharmaceutical composition in the form of tablets for oromucosal administration in treating infectious-inflammatory oropharyngeal diseases. The composition contains recombinant interferon specified in a group: recombinant interferon alpha, recombinant interferon beta, recombinant interferon gamma; amino acid specified in a group: arginine, histidine, glycine, glutathione, lysine, methionine, cysteine; an antiseptic, a preserving agent, flavours specified in a group: tea tree oil, eucalyptus leaf oil, mint leaf oil and a consistence base.
EFFECT: invention makes the composition applicable in fragile and frequently ill patients for reducing a disease recurrence.
7 cl, 1 ex
SUBSTANCE: pathogenetic treatment of chronic tonsillitis and/or hypertrophy of palatine tonsils in preschool children suffering from lymphoproliferative syndrome is ensured by the palatine tonsils debridement. An interleukin-1β(IL-1β) level is measured in the palatine tonsils washing. If the measured value is less than 5.8 pg/ml, recombinant interleukin-1β (IL-1β) is to be administered orally by phonophoresis with the use of the Tonsillor MM apparatus. Two courses of 10 procedures every 14 days are performed. The clinical effectiveness is assessed if observing a positive dynamics of IL-1β measured in the palatine tonsils washing 17 and 41 days after the beginning of the immunomodulatory therapy.
EFFECT: higher clinical effectiveness ensured by the differentiated selection of children for carrying out the immunomodulatory therapy, reducing a rate of infectious involvements of the palatine tonsils in the declared group of patients by the pathogenetically reasoned application of recombinant IL-1β.
3 cl, 2 tbl, 1 ex
SUBSTANCE: invention relates to medicine, namely to gastroenterology, and deals with the treatment of gastritis, stomach and duodenal ulcer. For this purpose a water solution of high-dispersive cluster silver with the concentration of 0.05-0.5 mg/ml is introduced inside in a dose of 30-50 ml 1-2 times per day for 10-30 days, or is applied on an injury focus in the process of endoscopic examination. In the latter case the solution of high-dispersive cluster silver with the concentration of 0.5-1.0 mg/ml is applied in a dose of 3-10 ml depending on the size of the injury focus.
EFFECT: method ensures the effective treatment of the said gastrointestinal diseases due to the increase of the specific antimicrobial and anti-inflammatory activity of nanosilver in the combination with its higher stability to inactivating factors of the stomach medium.